Establishment Labs Holdings: Buy Rating Backed by Motiva’s Superior Safety Profile

In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Establishment Labs Holdings (ESTA – Research Report), with a price target of $60.00.

Josh Jennings has given his Buy rating due to a combination of factors that highlight the competitive edge of Establishment Labs Holdings, particularly through its Motiva implants. The recent 5-year data on Motiva’s safety profile stands out when compared to similar follow-up data from US competitors such as Allergan, Mentor, and Sientra. This data underscores Motiva’s superior safety outcomes, which are expected to appeal strongly to US plastic surgeons.
Motiva’s revolutionary safety profile, as evidenced by the long-term follow-up data, sets it apart in the market. Jennings emphasizes that while direct comparisons across different trials can be complex, the 5-year and 6-year data from competitors provide a meaningful context that reinforces Motiva’s advantages. This compelling safety record is a significant factor in Jennings’s decision to rate Establishment Labs Holdings with a Buy, as it positions the company favorably against its competitors.

According to TipRanks, Jennings is a 4-star analyst with an average return of 3.3% and a 48.49% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Stereotaxis, Alphatec Holdings, and Boston Scientific.